Risk of subclinical atrial fibrillation in patients with cardiac implantable electronic devices after COVID-19 infection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20230324004

Enrollment

132

Registered

2023-03-24

Start date

2023-03-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk of subclinical atrial fibrillation after COVID-19 infection. subclinical atrial fibrillation pacemakers defibrillators post-COVID-19 long COVID-19

Interventions

Patients with a history of COVID-19 infection.,Patients without a history of COVID-19.

Other,Other

Post-COVID-19 patients,Non-COVID-19 patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cardiac implantable electronic devices (CIEDs) having atrial leads.

Exclusion criteria

Exclusion criteria: 1. Patients with previous cardiac surgery. 2. Patients with atrial fibrillation, atrial flutter or atrial tachycardia documenting from 12-lead ECG. 3. Patients with thyrotoxicosis, sepsis, electrolyte abnormalities, ESRD including renal replacement therapy. 4. Pregnant patients 5. Patients participating other concealed study.

Design outcomes

Primary

Measure	Time frame
Rate of subclinical atrial fibrillation Six months after COVID-19 infection. Rate of subclinical atrial fibrillation from device interrogation	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactKomsing Methavigul

Central Chest Institute of Thailand

hnueng@gmail.com66873409048

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026